FXR1 and cancer: FXR1 overexpression is regarded as a candidate biomarker predictive of poor survival in multiple solid tumors including NSCLCs and 18 types of human cancers, such as lung, cervix, head, breast, ovarian, and neck squamous carcinoma [28].